PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9425659

Can drugs be designed?

R E Hubbard
View original source ↗Export metadata ↓

Abstract

Many examples are now emerging of the successful use of rational, structure-based methods in drug discovery. Of particular note is the development of imaginative NMR-based methods for rapid routes to ligand design. Our understanding of the chemistry underlying protein-ligand interactions, however, remains relatively poor and a major limitation in our ability to truly design drugs.

Explore related subjects

Drug DesignLigandsMethodsProteinsRNAStructure-Activity RelationshipJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R E Hubbard. 1997. Can drugs be designed?. https://doi.org/10.1016/s0958-1669(97)80122-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Drug Design↗